FDA’s own advisory panel just voted 8-6 to hand back access to two peptides the agency restricted for safety reasons in 2023. The Pharmacy Compounding Advisory Committee recommended restoring BPC-157 and KPV to the 503A Bulk Drug Substances list, which lets compounding pharmacies make them without restriction. One member abstained.
BPC-157 is an unapproved synthetic anti-inflammatory peptide used off-label for ulcerative colitis and marketed in wellness circles as a soft-tissue healer. KPV, also anti-inflammatory, carries the same fitness-influencer following. Both landed on FDA’s safety-risk list in 2023, part of a 12-peptide reclassification that cited safety concerns and insufficient efficacy evidence.
The vote is the first of seven peptides the Pharmacy Compounding Advisory Committee reviews this week, and FDA doesn’t have to follow any of it. Health and Human Services Secretary Robert F. Kennedy Jr., a peptide user himself, has pushed to restore access, and FDA added eight new temporary voting members this week after conflict-of-interest complaints about panelists tied to peptide-selling clinics.
Here’s the real fight: CDER’s Russell Wesdyk told the panel FDA can’t set quality standards for BPC-157 because it can’t pin down what’s actually in it. “We can’t create quality standards until we know what it is,” he said. If the agency approves compounding anyway, it sets a template for the remaining five peptides on the docket, and for every gray-market peptide seller watching this week’s outcome as a bellwether for how much political pressure moves FDA science.
The other five votes decide how far this goes.
Sarah Chen